MNPR MONOPAR THERAPEUTICS Product Launches 8-K Filing 2025 - New Product Launches On May 7, 2025, Monopar Therapeutics announced a poster presentation on the long-term efficacy and safety of its drug candidate, ALXN1840, for Wilson disease at the EASL International Liver Congress 2025.Get access to all SEC 8-K filings of the MONOPAR THERAPEUTICS